MLYS vs MRNA: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
MRNA is the larger of the two ($79.58B market cap): the incumbent the market prices for continued execution (a loss expected next year, beta 1.17). MLYS is the smaller challenger ($1.24B), also expected to post a loss next year: more room to run, but more to prove. If you believe in growth, MRNA fits: analysts expect its revenue to rise 11% next year, against 0% for MLYS. If you believe MLYS's main driver (Lorundrostat FDA decision) pays off sooner, MLYS fits.
MLYS vs MRNA: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | MLYS | MRNA | What it tells you |
|---|---|---|---|
| Market cap | $1.24B | $79.58B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -5.76 | -46.96 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.82 | 1.17 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 1% of range | 67% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.46 | 11.62 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how MLYS and MRNA affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MLYS and MRNA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MLYS and MRNA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Mineralys Therapeutics (MLYS) do?
Mineralys Therapeutics (Nasdaq: MLYS), headquartered in Radnor, Pennsylvania, is a clinical-stage biopharmaceutical company focused on hypertension and related conditions driven by dysregulated aldosterone. Its lead and essentially only asset is lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor being developed for uncontrolled and resistant hypertension, with additional programs exploring chronic kidney disease (CKD) and obstructive sleep apnea (OSA). The company completed its Phase 3 program (including the Launch-HTN and Advance-HTN trials) and submitted a New Drug Application that the FDA accepted, with a PDUFA target action date of December 22, 2026. As of its August update, commercial leadership was in place, initial sales territories had been identified, and the company expected its sales force to be built before that date.
What does Moderna (MRNA) do?
Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.
MLYS vs MRNA: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- MLYS drivers: Lorundrostat FDA decision; Large uncontrolled-hypertension market.
- MRNA drivers: Respiratory franchise beyond COVID; Oncology optionality via Merck partnership.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. For MRNA, revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs.
MLYS or MRNA: which should you pick?
If the story you believe is MLYS's (Lorundrostat FDA decision), MLYS is the more direct way to own it; if it is MRNA's (Respiratory franchise beyond COVID), MRNA is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MLYS and MRNA guides.
MLYS vs MRNA: the full fundamentals
MLYS. Standard valuation multiples do not apply to Mineralys because it has no product revenue and posts ongoing losses funded by its cash balance. The roughly $1.2 billion market value, about 2 times its cash, down from about 2.8 times in October, reflects the market's probability-weighted view of lorundrostat's approval and future sales, not trailing fundamentals. The nine covering analysts rate it a strong buy with a mean target near $44, about three times the current price, though UBS cut its target to $19 in November, so the spread of views ahead of the December 22 decision is wide.
MRNA. MRNA trades on pipeline potential rather than current earnings: it is loss-making over the trailing year, revenue is far below its pandemic peak, and P/E is not meaningful. What changed in 2026 is the price of that option, with the stock up about 538% year to date to roughly 32 times trailing sales after the August Phase 3 melanoma success, even after a 17% drop on higher spending guidance in November. The 19 analysts Yahoo Finance tracks have a mean target near $165, under the $196.74 close, and consensus sees a loss of about $4.45 per share in 2027 on about $2.69 billion of revenue.
Headline figures (approximate, November 2026): MLYS shows product revenue (ttm) ~$0 (pre-commercial), cash & investments ~$624.7M (September 30, 2026); runway guided into 2028, q3 2026 net loss ~$57.3M; EPS -$0.64 vs ~-$0.54 consensus, q3 2026 operating costs R&D ~$22.7M; G&A ~$37.4M (up from ~$9.7M on launch build); MRNA shows market cap ~$80 billion, revenue (ttm) ~$2.5 billion, q3 2026 revenue ~$1.31 billion vs ~$892 million consensus, net income (ttm) ~-$2.8 billion.
The bottom line: MLYS vs MRNA
MLYS and MRNA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined MLYS and MRNA exposure against your real portfolio. It is not an investment adviser.
Wondering how MLYS or MRNA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Mineralys Therapeutics
Ask Walnut's AI anything about MLYS and see how it fits what you own.
FAQ
What is the difference between MLYS and MRNA?
+
Mineralys Therapeutics (Nasdaq: MLYS), headquartered in Radnor, Pennsylvania, is a clinical-stage biopharmaceutical company focused on hypertension and related conditions driven by dysregulated aldosterone. Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is MLYS or MRNA the better stock?
+
Neither is universally better. MRNA is the larger incumbent; MLYS is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, MLYS or MRNA?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both MLYS and MRNA?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of MLYS vs MRNA?
+
MLYS: The dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. Competition is real, most notably AstraZeneca's baxdrostat, another late-stage aldosterone synthase inhibitor with strong Phase 3 data, plus other emerging candidates. As a pre-revenue biotech, Mineralys burns cash, has raised equity, and now carries about $98 million of debt, creating dilution and leverage risk. Even with approval, commercial execution (payer coverage, physician adoption, and pricing in a market full of cheap generics) is uncertain. The stock is volatile and highly sensitive to regulatory news: it fell about 32% in the month to November 20, 2026 and closed at $13.90, near its 52-week low of about $13.58, against a high of about $44.13. MRNA: Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. The company is loss-making and burning cash, making it dependent on pipeline approvals landing on schedule. Regulatory risk is concrete: the FDA issued a Refusal-to-File letter for the flu vaccine earlier in 2026, and shifting U.S. vaccine policy adds uncertainty. Large legal settlements (such as the Arbutus and Genevant charge) can swing reported results, and much of the long-term value depends on the Merck-partnered cancer vaccine succeeding in Phase 3, which is far from guaranteed. Valuation risk is now acute: at about $80 billion the company trades near 32 times trailing sales, and the 19 analysts Yahoo Finance tracks have a mean target near $165 with a Hold rating, below the November 20 close (Jefferies cut its target to $215 from $230 on November 18). Higher spending is a newer risk: guidance for about $4 billion of 2027 cash costs sent the shares down about 17% in a week in November 2026, and debt has risen to about $4.2 billion. A delayed FDA filing or a regulatory setback for intismeran could reverse much of the gain. Walnut is not an investment adviser.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell MLYS or MRNA; figures are approximate and dated (as of November 2026). Verify current data before investing.